The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study

(2015) Shiv Saidha et al.   ANNALS OF NEUROLOGY

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

(2015) Ester Cantó et al.   BRAIN

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

(2015) J Kuhle et al.   Multiple Sclerosis Journal

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

(2015) Àlex Rovira et al.   Nature Reviews Neurology

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations

(2015) Kunio Nakamura et al.   NEUROIMAGE

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

(2015) Kathryn C. Fitzgerald et al.   JAMA Neurology

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

(2015) J Kuhle et al.   Multiple Sclerosis Journal

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study

(2014) Adipong Brickshawana et al.   LANCET NEUROLOGY

Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

(2014) Sandra Amor et al.   Multiple Sclerosis Journal

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

(2014) Jordi Río et al.   Multiple Sclerosis Journal

Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

(2014) Darin T. Okuda et al.   PLoS One

Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression

(2014) Alberto Ascherio et al.   JAMA Neurology

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis

(2013) J. Kuhle et al.   ACTA NEUROLOGICA SCANDINAVICA

Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature

(2013) Sunil Mahurkar et al.   AUTOIMMUNITY REVIEWS

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

(2013) Gilles Edan et al.   CNS DRUGS

Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients

(2013) M. Romeo et al.   EUROPEAN JOURNAL OF NEUROLOGY

The utility of multimodal evoked potentials in multiple sclerosis prognostication

(2013) Sudarshini Ramanathan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study

(2013) D. Paolicelli et al.   JOURNAL OF NEUROLOGY

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude

(2013) R. Dobson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis

(2013) L. Azzopardi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Body fluid biomarkers in multiple sclerosis

(2013) Manuel Comabella et al.   LANCET NEUROLOGY

Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis

(2013) Regina Schlaeger et al.   Multiple Sclerosis Journal

Clinical impact of early brain atrophy in clinically isolated syndromes

(2013) F Pérez-Miralles et al.   Multiple Sclerosis Journal

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

Mitoxantrone-related acute leukemia in MS: An open or closed book?

(2013) A. Chan et al.   NEUROLOGY

Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments

(2013) Erika Pietrolongo et al.   PLoS One

Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis

(2013) L.S. Wilson et al.   VALUE IN HEALTH

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

Personalized medicine in multiple sclerosis: hope or reality?

(2012) Tobias Derfuss   BMC Medicine

Advances in Imaging to Support the Development of Novel Therapies for Multiple Sclerosis

(2012) D H Miller et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era

(2012) Marylyn D. Ritchie   HUMAN GENETICS

Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis

(2012) H. Vrenken et al.   JOURNAL OF NEUROLOGY

Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study

(2012) Shiv Saidha et al.   LANCET NEUROLOGY

Measurement and clinical effect of grey matter pathology in multiple sclerosis

(2012) Jeroen JG Geurts et al.   LANCET NEUROLOGY

A Genetic Model Predicts the Response to Glatiramer Acetate in Two Different Cohorts (P05.129)

(2012) F. Macciardi et al.   NEUROLOGY

Serum IL-17F does not predict poor response to IM IFN -1a in relapsing-remitting MS

(2012) S. E. Bushnell et al.   NEUROLOGY

Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

(2012) Rajneesh Srivastava et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vivo Evaluation of Retinal Neurodegeneration in Patients with Multiple Sclerosis

(2012) Erika Tátrai et al.   PLoS One

Pharmacogenomics in neurology: Current state and future steps

(2011) Andrew Chan et al.   ANNALS OF NEUROLOGY

Magnetic Resonance Techniques in Multiple Sclerosis

(2011) Massimo Filippi   ARCHIVES OF NEUROLOGY

Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability

(2011) Stefan D Roosendaal et al.   Multiple Sclerosis Journal

Relapses do not matter in relation to long-term disability: No (they do)

(2011) Fred D Lublin   Multiple Sclerosis Journal

Risk of acute promyelocytic leukemia in multiple sclerosis: Coding variants of DNA repair genes

(2011) S. K. Hasan et al.   NEUROLOGY

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

(2011) J. Kuhle et al.   NEUROLOGY

Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI

(2011) J. J. G. Geurts et al.   NEUROLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis

(2010) Manuel Comabella et al.   BRAIN

Imaging biomarkers in multiple sclerosis

(2010) M. Filippi et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

(2010) C. Lukas et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

The changing demographic pattern of multiple sclerosis epidemiology

(2010) Nils Koch-Henriksen et al.   LANCET NEUROLOGY

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

(2010) Maria Pia Sormani et al.   Multiple Sclerosis Journal

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

(2010) Christoph Heesen et al.   Multiple Sclerosis Journal

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Spinal cord repair in MS: Does mitochondrial metabolism play a role?

(2010) O. Ciccarelli et al.   NEUROLOGY

Intracortical lesions: Relevance for new MRI diagnostic criteria for multiple sclerosis

(2010) M. Filippi et al.   NEUROLOGY

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

Evolving expectations around early management of multiple sclerosis

(2010) Ralf Gold et al.   Therapeutic Advances in Neurological Disorders

Black holes in multiple sclerosis: definition, evolution, and clinical correlations

(2009) M. A. Sahraian et al.   ACTA NEUROLOGICA SCANDINAVICA

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

(2009) S. Cotte et al.   BRAIN

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

(2009) F. Reed Johnson et al.   JOURNAL OF NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions

(2009) Navid Shiee et al.   NEUROIMAGE

A reassessment of the plateauing relationship between T2 lesion load and disability in MS

(2009) M. P. Sormani et al.   NEUROLOGY

Impact of multiple sclerosis relapses on progression diminishes with time

(2009) H. Tremlett et al.   NEUROLOGY

Cortical lesions in primary progressive multiple sclerosis: A 2-year longitudinal MR study

(2009) M. Calabrese et al.   NEUROLOGY

Early MRI in optic neuritis: The risk for disability

(2009) J. K. Swanton et al.   NEUROLOGY

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY

Magnetization Transfer Ratio in Gray Matter

(2008) Zhaleh Khaleeli et al.   ARCHIVES OF NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal